 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dutch investigators have found that treatment with ß-blockers in patients with COPD may reduce...
|
|
|
|
|
|
|
|
|
The presence of a major depressive episode (MDE) appears to be associated with an increased risk...
|
|
|
|
|
|
|
|
|
An AHRQ report that examines treatment options for cancers to the head and neck—including the...
|
|
|
|
|
|
|
|
|
The FDA has approved alglucosidase alfa (Lumizyme, Genzyme Corp.) for patients aged 8 and older...
|
|
|
|
|
|
|
Denosumab (Prolia, Amgen, Inc.) has been approved by the FDA to treat postmenopausal women with...
|
|
|
|
|
This Week's Feature Story
|
|
|
|
New Clinical Guidelines for Treating Exacerbations in Cystic Fibrosis
Cystic fibrosis (CF) is an inherited chronic disease that affects the lungs and digestive system of about 30,000 children and adults in the United States, according to the CF Foundation. Although the disease affects many organs, 85% of deaths in CF results from lung disease. CF is associated with progressive decline of lung function. Episodes of acute worsening of respiratory symptoms—or pulmonary exacerbations—frequently occur, and there are various clinical features associated with exacerbations (Table 1). “Pulmonary exacerbations have an adverse impact on patients’ quality of life and overall cost of care,” says Patrick A. Flume, MD. “They’re also the most common reason for hospitalization of CF patients. Identifying optimal treatment methods for pulmonary exacerbations in CF could lead to significant improvements in quality and length of life for patients living with the disease.”
[ More ]
|
|
|
|
|
|
|
